Suppr超能文献

经皮冠状动脉介入治疗期间并发症的经济负担。

The economic burden of complications during percutaneous coronary intervention.

作者信息

Jacobson Kurt M, Hall Long Kirsten, McMurtry Erin K, Naessens James M, Rihal Charanjit S

机构信息

Division of Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Qual Saf Health Care. 2007 Apr;16(2):154-9. doi: 10.1136/qshc.2006.019331.

Abstract

BACKGROUND

Technological advances have enabled percutaneous coronary intervention (PCI) to be applied with expanding indications. However, escalating costs are of concern. This study assessed the incremental medical costs of major in-hospital procedural complications incurred by patients undergoing PCI.

METHODS

We considered all patients undergoing elective, urgent, or emergent PCI at Mayo Clinic Rochester between 3/1/1998-3/31/2003 in analyses. Clinical, angiographic, and outcome data were derived from the Mayo Clinic PCI Registry. In-hospital PCI complications included major adverse cardiac and cerebrovascular events (MACCE) and bleeding of clinical significance. Administrative data were used to estimate total costs in standardised, year 2004, constant-US dollars. We used generalised linear modeling to estimate costs associated with complications adjusting for baseline and procedural characteristics.

RESULTS

1071 (13.2%) of patients experienced complications during hospitalisation. Patients experiencing complications were older, more likely to present with emergent PCI, recent or prior myocardial infarction, multi-vessel disease, and comorbid conditions than patients who did not experience these events. Unadjusted total costs were, on average, $27,865+/-$39,424 for complicated patient episodes compared to $12,279+/-$6796 for episodes that were complication free (p<0.0001). Adjusted mean costs were $6984 higher for complicated PCIs compared with uncomplicated PCI episodes (95% CI of cost difference: $5801, $8168). Incremental costs associated with isolated bleeding events, MACCE, or for both bleeding and MACCE events were $5883, $5086, and $15,437, respectively (p<0.0001).

CONCLUSIONS

This high-volume study highlights the significant economic burden associated with procedural complications. Resources and systems approaches to minimising clinical and economic complications in PCI are warranted.

摘要

背景

技术进步使得经皮冠状动脉介入治疗(PCI)的应用指征不断扩大。然而,成本不断上升令人担忧。本研究评估了接受PCI治疗的患者发生主要院内手术并发症的增量医疗成本。

方法

在分析中,我们纳入了1998年3月1日至2003年3月31日期间在罗切斯特梅奥诊所接受择期、紧急或急诊PCI的所有患者。临床、血管造影和结局数据来自梅奥诊所PCI注册中心。院内PCI并发症包括主要不良心脏和脑血管事件(MACCE)以及具有临床意义的出血。行政数据用于以2004年标准化不变美元估算总成本。我们使用广义线性模型来估算与并发症相关的成本,并对基线和手术特征进行调整。

结果

1071名(13.2%)患者在住院期间发生并发症。与未发生这些事件的患者相比,发生并发症的患者年龄更大,更有可能接受急诊PCI、近期或既往心肌梗死、多支血管病变以及合并症。未调整的复杂患者事件的平均总成本为27,865美元±39,424美元,而无并发症事件的平均总成本为12,279美元±6,796美元(p<0.0001)。与未发生并发症的PCI事件相比,发生并发症的PCI事件调整后的平均成本高6984美元(成本差异的95%置信区间:5801美元,8168美元)。与单纯出血事件、MACCE或出血和MACCE事件相关的增量成本分别为5883美元、5086美元和15,437美元(p<0.0001)。

结论

这项大规模研究突出了与手术并发症相关的巨大经济负担。有必要采取资源和系统方法来尽量减少PCI中的临床和经济并发症。

相似文献

1
The economic burden of complications during percutaneous coronary intervention.
Qual Saf Health Care. 2007 Apr;16(2):154-9. doi: 10.1136/qshc.2006.019331.
3
Hospital resources consumed in treating complications associated with percutaneous coronary interventions.
Am J Cardiol. 2006 Feb 1;97(3):322-7. doi: 10.1016/j.amjcard.2005.08.047.
7
Effect of gender and race on outcomes in dialysis-dependent patients undergoing percutaneous coronary intervention.
Am J Cardiol. 2011 May 1;107(9):1319-23. doi: 10.1016/j.amjcard.2010.12.042. Epub 2011 Feb 23.

引用本文的文献

1
Point-of-Care Ultrasound for the Detection of Vascular Access Site Complications-The ULTRASITCOM Study.
J Soc Cardiovasc Angiogr Interv. 2025 Feb 18;4(2):102516. doi: 10.1016/j.jscai.2024.102516. eCollection 2025 Feb.
2
Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures.
Nat Rev Cardiol. 2025 Apr;22(4):273-303. doi: 10.1038/s41569-024-01076-0. Epub 2024 Oct 11.
3
Transradial Access for High-Risk Percutaneous Coronary Intervention: Implications of the Risk-Treatment Paradox.
Circ Cardiovasc Interv. 2021 Jul;14(7):e009328. doi: 10.1161/CIRCINTERVENTIONS.120.009328. Epub 2021 Jul 13.
4
Effects of progranulin on the pathological conditions in experimental myocardial infarction model.
Sci Rep. 2020 Jul 16;10(1):11842. doi: 10.1038/s41598-020-68804-7.
8
The volume-outcome relationship in laparoscopic cholecystectomy: a population-based study using propensity score matching.
Surg Endosc. 2013 Sep;27(9):3139-45. doi: 10.1007/s00464-013-2867-x. Epub 2013 Apr 26.

本文引用的文献

3
Hospital resources consumed in treating complications associated with percutaneous coronary interventions.
Am J Cardiol. 2006 Feb 1;97(3):322-7. doi: 10.1016/j.amjcard.2005.08.047.
4
Handling missing data in patient-level cost-effectiveness analysis alongside randomised clinical trials.
Appl Health Econ Health Policy. 2005;4(2):65-75. doi: 10.2165/00148365-200504020-00001.
8
Multiple regression of cost data: use of generalised linear models.
J Health Serv Res Policy. 2004 Oct;9(4):197-204. doi: 10.1258/1355819042250249.
9
Economic impact of drug-eluting stents on hospital systems: a disease-state model.
Am Heart J. 2004 Mar;147(3):449-56. doi: 10.1016/j.ahj.2003.11.005.
10
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
N Engl J Med. 2004 Jan 15;350(3):221-31. doi: 10.1056/NEJMoa032441.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验